✦ LIBER ✦

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

✍ Scribed by Adam Brufsky, Vicente Valero, Beatrice Tiangco, Shaker Dakhil, Arija Brize, Hope S. Rugo, Ragene Rivera, Anja Duenne, Naima Bousfoul, Denise A. Yardley

Book ID: 113062450
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 402 KB
Volume: 133
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2008-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-Line Bevacizumab-Containing Therap

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

✍ Thomssen, Christoph; Pierga, Jean-Yves; Pritchard, Kathleen I.; Biganzoli, Laura 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 375 KB

Adjuvant bevacizumab-containing therapy

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

✍ Cameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 544 KB

First-line bevacizumab in combination wi

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

✍ Miles, D. W.; Dieras, V.; Cortes, J.; Duenne, A.- A.; Yi, J.; O'Shaughnessy, J. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 426 KB

5016 Efficacy in patient subgroups in RI

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

✍ V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

476 PFS by patient subgroup for standard

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Phase I trial of the oral PARP inhibitor

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

✍ Dent, Rebecca A; Lindeman, Geoffrey J; Clemons, Mark; Wildiers, Hans; Chan, Arle 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 207 KB